Address: Krylatskaya str. 17/3, Moscow 121614,Russia
Tel: +7 (495) 755-83-57
Web: http://www.janssencilag.ru/
Janssen represents the pharmaceutical sector of Johnson & Johnson family of companies. Founded 125 years ago, Johnson & Johnson is the most comprehensive manufacturer of health care products in the world. Johnson & Johnson has more than 250 companies located in 57 countries around the world, employing 114,000 men and women active in three company segments : Consumer Goods, Medical Devices & Diagnostics and Pharmaceuticals. In 2010 total sales exceeded 61 billion dollars, and 6.8 billion dollars were invested in R&D.
Janssen started operations in Russia in 1991. Today Janssen is one of the top 10 leading pharmaceutical companies on the Russian market and continues to deliver innovative pharmaceutical products and solutions, improving of quality of lives of millions of Russians.
Janssen Pharmaceutical Companies of Johnson & Johnson are dedicated to addressing and solving important unmet medical needs, including oncology (e.g. multiple myeloma and prostate cancer), immunology (e.g. psoriasis), neuroscience (e.g. schizophrenia, dementia and pain), infectious disease (e.g. HIV/AIDS, Hepatitis C and tuberculosis), and cardiovascular and metabolic diseases (e.g. diabetes).
Maria Fernanda Prado highlights some of the lessons drawn from her extensive experience in emerging markets which remain applicable in her current role as Janssen’s managing director for the Benelux…
Christian Rodseth, VP and managing director for Janssen’s Greece, Poland, and Romania cluster, outlines the multifaceted strengths of his teams, the part of the Janssen portfolio he is most excited…
Jamie Phares, Managing Director, Janssen, the Pharmaceutical Companies of Johnson & Johnson in the GCC, comments on the evolving approach to healthcare provision in the region, the role of Saudi…
Julie Enevold Brooker discusses what she sees as Janssen’s responsibility to help improve the Danish healthcare system beyond just bringing innovative medicines to patients, gives her thoughts on the new…
Janssen’s Managing Director for Turkey, Demet Russ, discusses her return to the country after 25 years abroad, having worked for Johnson & Johnson in different local, regional and global roles…
Janssen’s Cyril Titeux highlights the commonalities and challenges within his 31-country portfolio, his hopes and expectations for the evolution of market access in the region, and some of the key…
Dr Johan Van Hoof, global therapeutic area head of vaccines for Janssen, shares his extensive career experience in vaccines; the learnings from Janssen’s Ebola vaccine; and his key message to…
Janssen Norway’s Mario Klesse shares his first impressions of the Norwegian pharma market, his strategic priorities for the affiliate, how Janssen is defining and meeting unmet patient needs, key access…
Urs Vögeli, managing director for Janssen Switzerland, outlines the importance of the Swiss operations to Janssen, his interesting career journey, Janssen’s commitment to bringing transformational medical innovations to Swiss patients,…
Janssen in Belgium was founded in 1953 by Dr Paul Janssen, with only one thing in mind: saving people’s lives through the development of better medicines. In 1961, the company…
Myriem Tamimy gives an overview of the ongoing situation for Janssen and pharma multinationals more generally in Morocco, discusses the next steps in the authorities’ pharma strategy and the role…
Sévan Kaloustian shares his first impressions of the Romanian healthcare ecosystem and pharmaceutical market as newly appointed managing director of Janssen Pharmaceutical Companies of Johnson & Johnson Romania. Kaloustian outlines…
Martin Minarovič, Janssen’s country director Czech Republic, discusses the success factors behind the company’s strong growth, not only in terms of revenue but more importantly in terms of the number…
Vishnu Kalra, Janssen’s managing director for the GCC region, reflects on his 18-year career with Johnson & Johnson, including his perspective on the success factors behind the company’s strong growth…
Ana Raposo, country director for Gulf Countries at Janssen discusses her role, the main similarities and differences between the various markets throughout the Gulf, mental health, and corporate social responsibility…
Shuhei Sekiguchi, recently-appointed managing director of Janssen Taiwan, discusses how his vast experience in marketing and sales will help him in this new role, Janssen´s market outlook for Taiwan, its…
Berkeley Vincent, managing director of Janssen in the Nordics and Baltics, discusses the challenges of the digital future for the Swedish affiliate and the whole healthcare industry and highlights Janssen’s…
In this exclusive and wide-ranging interview, Janssen’s EMEA head Kris Sterkens outlines the company’s strategies in Europe, its increasing embrace of digital solutions, and the shift toward pre-emptive and precision…
Ramez Mohsen, managing director at Janssen for Egypt, Jordan, Libya & Sudan, highlights how the company is driving real access to treatments in Egypt through collaboration with various stakeholders. He…
Thibault Janssens, managing director of Bolloré Logistics Korea, shares his expert opinion on the Asian logistics market, and explains how a constant customer-centric focus catering to the specific needs of…
Asgar Rangoonwala, president of Xian Janssen, Janssen’s Chinese affiliate, shares the key milestones for the affiliate in the past two years, how Janssen is investing in bringing new innovations to…
Emmanuelle Quilès, CEO of Janssen France, speaks about how she joined the American multinational with the ambition to bring digitalization and transform the organization from the inside. Quilès goes on…
Rogier Janssens, GM of the Biopharma business of Merck KGaA, Darmstadt, Germany in China, shares the highlights of his first 16 months at the affiliate; the impact of the regulatory…
Maria Fernanda Prado, managing director of Janssen Turkey, elaborates on the unique dynamics at play in Turkey; an important emerging market. Prado addresses the challenges, advantages, and opportunities that exist…
Loic Galmard discusses the opportunities and challenges of setting up local production in Algeria, and the best strategies to increase market access and create a dialogue with the regulatory authorities.…
Filipa Costa returned to Portugal in September 2016 to take on the leadership of the fastest growing multinational affiliate in the country – Janssen. In this interview, she reveals her…
Mark Hicken, managing director of the UK and Ireland operations of Janssen, the pharmaceutical arm of Johnson & Johnson, highlights the company’s long-standing R&D presence in the UK. He calls…
Aki Kasvi and Mindaugas Plieskis of Janssen Baltics discuss their strategic priorities, acting as a strategic partner within the region, and ensuring that patients can access their innovative latest-generation therapies…
A passionate advocate for Indian patients, Sanjiv Navangul, managing director of Janssen India, discusses the company’s public health work in the field of tuberculosis (TB) and multi-drug resistant TB (MDR-TB)…
Bruno Costa Gabriel, managing director of Janssen Brazil, provides insights into the transformative market approach successfully implemented by this leading company in Brazil and his main priorities to further leverage…
Yolanda Alagón, general manager of Janssen Colombia, discusses the company’s footprint in Colombia and Latin America and her strategy for the affiliate moving forward. You have been appointed General Manager…
Efthymios (Makis) Papataxiarchis, Managing Director of Janssen Pharmaceutical companies, Johnson & Johnson Greece, Malta & Cyprus, on spearheading a large multinational company through the largest economic crisis in Europe. He…
Mario Sturion, the recently appointed general manager of Janssen Mexico, assesses the specific challenges and opportunities of the Mexican health system and explains how a customized market access approach has…
Janssen’s company group chairman for Asia Pacific, Kris Sterkens distills the core elements of what it means to be a transformational medical innovator, while exclaiming how this characterization has molded…
Dr. Leisha Daly, Janssen Ireland country director and president of the Irish Pharmaceutical Healthcare Association (IPHA) discusses her presidency and the conclusion of a four-year agreement between IPHA and the…
Janssen Switzerland’s Ludo Ooms highlights the strengths of the Swiss healthcare and life sciences sector including the efficiency of the government, a productive and well trained workforce, the national pricing…
The managing director of Janssen Hungary, Andreas Woitossek, depicts the valuable role of real-world evidence in enabling the affiliate’s consistent double-digit growth over the last four years, while highlighting the…
Janssen Czech Republic’s MD reviews his longstanding career within the company and highlights how founder Dr. Paul Janssen’s legacy still influences operations today. He also compares the Czech regulatory environment…
In an exclusive interview at the eyeforpharma Barcelona Summit 2016, Janssen EMEA’s Jane Griffiths speaks out about patient-centricity, sustainability and the dawning of a new world of healthcare. What’s been keeping you…
While growth forecasts for the MENA region remain high, falling oil prices and political instability are creating significant government budgetary challenges for the industry to adapt to. Janssen’s area managing…
Paul Korte, General Manager for Janssen in the Netherlands, highlights the strategic move and leadership position taken up by Janssen in the oncology field, and calls on Dutch healthcare stakeholders…
Lygature is the new name of TI Pharma and CTMM, two internationally renowned public-private-partnerships turned non-for-profit partnership drivers. Managing Director Jorg Janssen explains that it will be business as usual…
John O’Hara is the general manager and vice president of Janssen’s facilities in Puerto Rico as well as the head of the Janssen campus. He discusses the affiliate’s rapid growth…
The country manager of one of the foremost providers of sustainable and integrated healthcare solutions describes the sorts of local adaptations that need to be enacted when launching a product on the…
Janssen’s MD in Turkey discusses how true innovation is still recognized in Turkey, and how products that meet unmet medical needs are given early access to the country and reimbursement.…
Eric Alvarez, managing director of Janssen Mexico, explains why it is important to distinguish between the public and private sector when discussing the latest developments in the pharmaceutical industry, and…
Janssen’s managing director in Korea discusses the groups long and significant commitment to R&D in the country, as well as some of the challenges that one of the most innovative…
The country manager of a JNJ affiliated company advocates deploying electronic healthcare techniques to transform the reach of local practitioners and speaks out about the sort of local adaptations that…
Long-term strategy is the name of the game for Janssen. Alejandro Smolje, the company’s director of finance for Latin America South, outlines how that strategy is implemented in Argentina and…
Erich Viertel Molina, country manager at Janssen Chile speaks about Janssen’s commitment to the health of Chileans. Over the past years Janssen successfully launched several products to the Chilean market…
As a company focused entirely on innovation, Janssen has remained dedicated to bringing groundbreaking new products to Portugal, ensuring access in Portugal is as stellar as anywhere else. Gisella Dante,…
Jason Carroll, General Manager of Janssen Philippines, discusses what it will take to put Janssen Philippines on the map as one of the largest, most reputable pharmaceutical companies in the…
Jan Van der Goten, GCC Managing Director of Janssen UAE, talks about his experience at Janssen GCC as regional manager, how collaboration with other companies in the industry will bring…
Janssen has historically had a very strong focus on emerging markets. In today’s world, where growth for the pharmaceutical industry overwhelmingly comes from emerging markets, where do we find the…
Let’s start by introducing you to our readers. Could you briefly describe what attracted you to Janssen originally, and share with us a brief summary of your experience working in…
Mr. Heyman, you inherited the chair and management of Janssen Pharmaceutica. What core values and spirit of Dr. Paul Janssen were you asked by the Janssen family to perpetuate throughout…
Mr. Heyman, you inherited the chair and management of Janssen Pharmaceutica. What core values and spirit of Dr. Paul Janssen were you asked by the Janssen family to perpetuate throughout…
After a significant experience in consumer goods at Procter & Gamble, you have been managing director of Janssen Turkey for 11 years. Over this last decade, the Turkish pharma market…
After a significant experience in consumer goods at Procter & Gamble, you have been managing director of Janssen Turkey for 11 years. Over this last decade, the Turkish pharma market…
Infirmary and ultimately leading to a position heading the Czech Republic and Slovakian organization for Janssen. Can you begin by introducing yourself to our readers and giving them an overview…
Can you please start by giving to our readers an overview of your background and your involvement with Janssen? I am a Public Health graduate and have completed an MBA…
Janssen-Cilag has been investing heavily in its Latin American operations in the past years. What is the relative importance of the Chilean operations for Janssen-Cilag in Latin America and what…
Hungary is one of the largest pharmaceutical markets in the region, and has been used by Janssen-Cilag as a hub. Can you elaborate on how important Hungary is for Janssen-Cilag…
Janssen recently signed memorandums of understanding with both the Skolkovo Foundation and ChemRar. Can you describe the strategic parameters and intended outcomes of these agreements? How do they factor into…
How does Janssen view the Serbian market today, and how has company built up its presence here in the country? Previously we were working through distribution channels and in 2003…
Janssen-Cilag is involved in not only selling its products in France but research and production as well. As France is a leading subsidiary, can you speak to the importance of…
When we spoke to Javier Lombar of IMS Argentina, he explained that a lot of multinational companies use Argentina as a base for regional operations. How does Janssen-Cilag operate in…
Although Russian authorities received heavy criticism for approving the Sputnik V vaccine prior to the completion of Phase III clinical trials, the jab is increasingly being seen as a viable…
Russia has announced that a domestically developed COVID-19 vaccine has been approved by its health authorities, the first such approval globally. However, with large-scale Phase III trials having not yet…
Below is a selection of top stories in Russian pharma from recent months, ranging from proposed changes in legislation, labelling system updates, priorities set forth by the country’s manufacturing association…
Russia is facing a drug shortage crisis which is having a particular impact on patients with life-threatening conditions. A combination of geopolitical and bureaucratic issues are restricting the flow of…
In the latest twist in the ongoing story of Russian interference in the US presidential elections of 2016, it has emerged that Russian internet trolls and automated bots spread misinformation…
In the United States, Johnson & Johnson has an image of being very close to people. Americans grow up with this company — from baby shampoo, to Tylenol when they…
You took over this organization just three months ago, having previously headed businesses in industries as diverse as retail, food, and automobiles. What drew you to Alliance Healthcare Russia? Do…
The ARPM was founded in 2002, and you were its director from 2002-2004, before leaving for a post at the Roszdravnadzor. You’ve since rejoined as director since 2007. The organization…
When Focus Reports prepared a report on the French pharmaceutical industry in 2009/10, we found that the head of the main multinational pharmaceutical association had taken a career path quite…
The U.S. and Russia have a long history of trade, and you have personally been with the American Chamber of Commerce in Russia since 2001. Can you give a brief…
The primary objectives of this association are to promote Russia as a clinical trial destination, optimize the regulatory and legislative environment, and promote the interests of ACTO members. Can you…
You have said that AstraZeneca intends to be “in Russia for Russia” and the company has recently announced a large-scale investment in this country, financing a $150Mn domestic facility in…
See our Cookie Privacy Policy Here
